<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01250002</url>
  </required_header>
  <id_info>
    <org_study_id>STU00025240</org_study_id>
    <nct_id>NCT01250002</nct_id>
  </id_info>
  <brief_title>Lidocaine and Outpatient Gynecologic Laparoscopy</brief_title>
  <official_title>The Effect of Perioperative Systemic Lidocaine on Quality of Recovery After Outpatient Gynecologic Laparoscopy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Northwestern University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Northwestern University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Although ambulatory gynecological laparoscopy is considered to be a minimally invasive
      surgical procedure, only 60% of patients undergoing this procedure are satisfied with
      postoperative pain control. Postoperative pain can lead to physiological, immunological and
      psychological derangements in patients.It also has been shown to be the most common cause of
      hospital admission after outpatient surgery.

      Opioids constitute the most commonly used pain management strategy after surgery, however
      they have many undesirable side effects including nausea, vomiting and respiratory
      depression. Different strategies have been developed to decrease the amount of opioid
      required after surgery. Opioid sparing drugs as well as regional anesthesia have been shown
      to be effective. Systemic administration of lidocaine has been shown to decrease opioid
      consumption, improve recovery of bowel function and promote a better recovery after inpatient
      procedures. Lidocaine has been shown to have analgesic, antihyperalgesic and
      anti-inflammatory properties. It also has an excellent safety profile when give by a low-dose
      infusion.

      The improvement of surgical technique and anesthesia care has made major adverse outcomes
      infrequent, especially in the ambulatory setting. Assessing patient's quality of recovery has
      become an important outcome in several studies. The patient's capacity to return to his
      normal activities is one of the most important sign of a successful outpatient procedure and
      it has significant economic implications.

      Quality of recovery -40(QoR-40) is a validated 40 item instrument to assess the quality of
      post-operative recovery. Myels et al. have concluded that the QoR-40 would be a useful
      outcome measure to assess the impact on changes in health care delivery, but anesthesia
      studies underutilize this instrument.

      The research question for the study is; does the use of systemic perioperative lidocaine
      improve quality of recovery after outpatient laparoscopy?
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      70 subjects will be randomly allocated into 2 groups, using a computer generated table of
      random numbers. Group A (study group) will receive lidocaine. Group B (control group) will
      receive the same volume of saline infusion. The study drugs will be prepared by one of the
      investigators in the study. Subjects will be recruited up to 21 days prior to surgery.They
      will be premedicated with intravenous (IV) midazolam 0.04 mg/kg. Routine ASA monitors will be
      applied. Anesthesia will be induced with remifentanil infusion started at 0.1 mcg/kg/minute
      titrated to keep blood pressure within 20% of the baseline and propofol 1.0 -2.0 mg/kg. Group
      A will receive lidocaine 1.5mg/kg bolus and Group B the equivalent volume of saline. Subjects
      will be monitored with a 5 lead EKG throughout the lidocaine administration and if any
      arrhythmia is detected. The study drug will be stopped and investigators unblinded.

      Tracheal intubation will be facilitated with rocuronium (0.6 mg/kg) or succinylcholine (1-2mg
      /kg). Immediately after the induction, group A will receive lidocaine infusion (2 mg/kg/hr
      IV). Group B will receive the equivalent volume of saline; both infusions will be continued
      until 1 hour after arrival in the PACU. Anesthesia will be maintained with desflurane
      titrated to maintain a bispectral index (BIS) between 40-60 , remifentanil infusion started
      at 0.1mcg/kg/min titrated to keep blood pressure within 20 % of baseline values , and
      rocuronium that will be administered at the discretion of the anesthesiologist. Upon
      termination of the surgery, neuromuscular blockade will be antagonized with a combination of
      neostigmine 0.05mg/kg and glycopyrrolate 0.01 mg/kg. Ondansetron 4 mg IV will be administered
      to prevent postoperative nausea and vomiting. Subject will be evaluated for pain in the OR
      after extubation, using a numeric rating scale, if pain greater than 4/10 they will receive
      hydromorphone (10 mcg/kg IV). In PACU, subjects will receive IV hydromorphone in divided
      doses as needed to achieve a verbal rating score for pain &lt;4 out of 10 and they will be
      evaluated every 15 minutes .They will also receive metoclopramide (20 mg IV ) as rescue
      antiemetic in PACU. Discharge readiness will be assessed by a PACU nurse using the modified
      Post Anesthesia Discharge Scoring System (MPADSS) score every 15 minutes for about 3 hours or
      until ready for discharge.The primary and secondary outcomes will be assessed by an
      independent observer who will be blinded to group allocation. Study personnel will contact
      the subject at 24 hours to assess well being, (nausea, vomiting and opioid consumption.
      Subject will be contacted by telephone by the study staff and will complete the Modified
      Quality of Recovery 40 (MQOR40) at 24 hours post surgery.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">September 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quality of Recovery 40 Score</measure>
    <time_frame>24 hours post surgery</time_frame>
    <description>Quality of recovery 40 score on the day after surgery. Scale ranges from a low of 40 (poor recovery) to a high of 200 (good recovery).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Opioid Consumption (Morphine Equivalents)</measure>
    <time_frame>24 hours</time_frame>
    <description>opioid consumption (morphine equivalents)post operatively</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">70</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Lidocaine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo will receive the same volume of saline infusion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo will receive the same volume of saline infusion.</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>Lidocaine administration 1.5 mg/kg bolus followed by a 2 mg/kg/hr infusion via intravenous catheter</description>
    <arm_group_label>Lidocaine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female patients undergoing outpatient laparoscopic gynecologic surgery

          -  American society of anesthesiologists class (ASA) Physical status (PS) I and II

          -  Age between 18 and 64 years

          -  Fluent in English

          -  Body mass index (BMI) less than 35

        Exclusion Criteria:

          -  History of allergy to local anesthetics

          -  History of chronic opioid use

          -  Pregnant patients

          -  Body Mass Index (BMI) greater than 35

          -  History of electrocardiogram (EKG) abnormalities

          -  Hepatic Impairment

          -  History of congestive heart failure

          -  Electrocardiogram (EKG) abnormalities

          -  History of heart block (subject with history of heart block)

          -  Current use of anti-arrhythmic medications

        Drop -Outs:

          -  Patient or surgeon request

          -  Conversion of the surgery from laparoscopic to open
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gildasio De Oliveira, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Northwestern University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Prentice Womens Hospital</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60611</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Lovatsis D, Jos√© JB, Tufman A, Drutz HP, Murphy K. Assessment of patient satisfaction with postoperative pain management after ambulatory gynaecologic laparoscopy. J Obstet Gynaecol Can. 2007 Aug;29(8):664-7.</citation>
    <PMID>17714620</PMID>
  </reference>
  <reference>
    <citation>Kehlet H, Holte K. Effect of postoperative analgesia on surgical outcome. Br J Anaesth. 2001 Jul;87(1):62-72. Review.</citation>
    <PMID>11460814</PMID>
  </reference>
  <reference>
    <citation>McKay A, Gottschalk A, Ploppa A, Durieux ME, Groves DS. Systemic lidocaine decreased the perioperative opioid analgesic requirements but failed to reduce discharge time after ambulatory surgery. Anesth Analg. 2009 Dec;109(6):1805-8. doi: 10.1213/ANE.0b013e3181be371b.</citation>
    <PMID>19923506</PMID>
  </reference>
  <reference>
    <citation>White PF. The changing role of non-opioid analgesic techniques in the management of postoperative pain. Anesth Analg. 2005 Nov;101(5 Suppl):S5-22. Review.</citation>
    <PMID>16334489</PMID>
  </reference>
  <reference>
    <citation>Koppert W, Weigand M, Neumann F, Sittl R, Schuettler J, Schmelz M, Hering W. Perioperative intravenous lidocaine has preventive effects on postoperative pain and morphine consumption after major abdominal surgery. Anesth Analg. 2004 Apr;98(4):1050-5, table of contents.</citation>
    <PMID>15041597</PMID>
  </reference>
  <reference>
    <citation>Groudine SB, Fisher HA, Kaufman RP Jr, Patel MK, Wilkins LJ, Mehta SA, Lumb PD. Intravenous lidocaine speeds the return of bowel function, decreases postoperative pain, and shortens hospital stay in patients undergoing radical retropubic prostatectomy. Anesth Analg. 1998 Feb;86(2):235-9.</citation>
    <PMID>9459225</PMID>
  </reference>
  <reference>
    <citation>Kaba A, Laurent SR, Detroz BJ, Sessler DI, Durieux ME, Lamy ML, Joris JL. Intravenous lidocaine infusion facilitates acute rehabilitation after laparoscopic colectomy. Anesthesiology. 2007 Jan;106(1):11-8; discussion 5-6.</citation>
    <PMID>17197840</PMID>
  </reference>
  <reference>
    <citation>Marret E, Rolin M, Beaussier M, Bonnet F. Meta-analysis of intravenous lidocaine and postoperative recovery after abdominal surgery. Br J Surg. 2008 Nov;95(11):1331-8. doi: 10.1002/bjs.6375. Review.</citation>
    <PMID>18844267</PMID>
  </reference>
  <reference>
    <citation>Gill TM, Feinstein AR. A critical appraisal of the quality of quality-of-life measurements. JAMA. 1994 Aug 24-31;272(8):619-26.</citation>
    <PMID>7726894</PMID>
  </reference>
  <reference>
    <citation>Guyatt GH, Cook DJ. Health status, quality of life, and the individual. JAMA. 1994 Aug 24-31;272(8):630-1.</citation>
    <PMID>8057520</PMID>
  </reference>
  <reference>
    <citation>Watcha MF, Issioui T, Klein KW, White PF. Costs and effectiveness of rofecoxib, celecoxib, and acetaminophen for preventing pain after ambulatory otolaryngologic surgery. Anesth Analg. 2003 Apr;96(4):987-94, table of contents.</citation>
    <PMID>12651647</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Hunt JO, Nightingale CE, Fletcher H, Beh T, Tanil D, Nagy A, Rubinstein A, Ponsford JL. Development and psychometric testing of a quality of recovery score after general anesthesia and surgery in adults. Anesth Analg. 1999 Jan;88(1):83-90.</citation>
    <PMID>9895071</PMID>
  </reference>
  <reference>
    <citation>Myles PS, Weitkamp B, Jones K, Melick J, Hensen S. Validity and reliability of a postoperative quality of recovery score: the QoR-40. Br J Anaesth. 2000 Jan;84(1):11-5.</citation>
    <PMID>10740540</PMID>
  </reference>
  <verification_date>June 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 27, 2010</study_first_submitted>
  <study_first_submitted_qc>November 29, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 30, 2010</study_first_posted>
  <results_first_submitted>March 5, 2012</results_first_submitted>
  <results_first_submitted_qc>June 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 21, 2013</results_first_posted>
  <last_update_submitted>June 25, 2014</last_update_submitted>
  <last_update_submitted_qc>June 25, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 26, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Northwestern University</investigator_affiliation>
    <investigator_full_name>Gildasio De Oliveira</investigator_full_name>
    <investigator_title>Gildasio De Oliveira, M.D. Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Pain</keyword>
  <keyword>MQOR 40</keyword>
  <keyword>Lidocaine</keyword>
  <keyword>Gynecologic</keyword>
  <keyword>Surgery</keyword>
  <keyword>Laparoscopic</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lidocaine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were recruited in the preoperative area of the hospital between November 2010 and September 2011.</recruitment_details>
      <pre_assignment_details>All participants were assigned to groups.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Group A (Study Group) Lidocaine</title>
          <description>Group A (study group) Lidocaine administration</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Group B (control group) will receive the same volume of saline infusion.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="35"/>
                <participants group_id="P2" count="35"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="31"/>
                <participants group_id="P2" count="32"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Change to open surgical procedure</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Group A (Study Group) Lidocaine</title>
          <description>Group A (study group) Lidocaine administration</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Group B (control group) will receive the same volume of saline infusion.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="35"/>
            <count group_id="B2" value="35"/>
            <count group_id="B3" value="70"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.2" spread="8.6"/>
                    <measurement group_id="B2" value="39.1" spread="9.3"/>
                    <measurement group_id="B3" value="38.2" spread="9.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="35"/>
                    <measurement group_id="B2" value="35"/>
                    <measurement group_id="B3" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Quality of Recovery 40 Score</title>
        <description>Quality of recovery 40 score on the day after surgery. Scale ranges from a low of 40 (poor recovery) to a high of 200 (good recovery).</description>
        <time_frame>24 hours post surgery</time_frame>
        <population>Intent to treat.</population>
        <group_list>
          <group group_id="O1">
            <title>Group A (Study Group) Lidocaine</title>
            <description>Group A (study group) Lidocaine administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group B (control group) will receive the same volume of saline infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Quality of Recovery 40 Score</title>
          <description>Quality of recovery 40 score on the day after surgery. Scale ranges from a low of 40 (poor recovery) to a high of 200 (good recovery).</description>
          <population>Intent to treat.</population>
          <units>units on a scale</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="175" lower_limit="160" upper_limit="183"/>
                    <measurement group_id="O2" value="157.5" lower_limit="142.5" upper_limit="173.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Opioid Consumption (Morphine Equivalents)</title>
        <description>opioid consumption (morphine equivalents)post operatively</description>
        <time_frame>24 hours</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Group A (Study Group) Lidocaine</title>
            <description>Group A (study group) Lidocaine administration</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Group B (control group) will receive the same volume of saline infusion.</description>
          </group>
        </group_list>
        <measure>
          <title>Opioid Consumption (Morphine Equivalents)</title>
          <description>opioid consumption (morphine equivalents)post operatively</description>
          <units>mg</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="31"/>
                <count group_id="O2" value="32"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20" lower_limit="0" upper_limit="30"/>
                    <measurement group_id="O2" value="30" lower_limit="15" upper_limit="35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>2 Days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Group A (Study Group) Lidocaine</title>
          <description>Group A (study group) Lidocaine administration</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Group B (control group) will receive the same volume of saline infusion.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (10.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="35"/>
                <counts group_id="E2" events="17" subjects_affected="17" subjects_at_risk="35"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="35"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="35"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Quality of recovery (QOR-40) instrument validation was performed in the in-patient setting and formal validation for the outpatient setting is still lacking.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gildasio De Oliveira, MD</name_or_title>
      <organization>Northwestern University</organization>
      <phone>312-926-8373</phone>
      <email>g-jr@northwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

